Theravance Biopharma, Inc.

NASDAQ•TBPH

CEO: Mr. Rick E. Winningham M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2014-05-16

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Contact Information

901 Gateway Boulevard, South San Francisco, CA, 94080, United States

650-808-6000

www.theravance.com

Market Cap

$698.27M

P/E (TTM)

23.7

17.9

Dividend Yield

52W High

$21.03

52W Low

$7.90

52W Range

45%

Rank55Top 80.0%

2.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$19.99M+18.51%

4-Quarter Trend

EPS

$0.07-126.92%

4-Quarter Trend

FCF

-$6.51M+24.89%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Net Income Surge Net income reached $44.9M for nine months, driven by $75.1M gain from TRELEGY royalty sale.

Total Revenue Increased 35% Total revenues hit $61.6M for nine months, boosted by $7.5M China regulatory milestone payment.

Strong Operating Cash Flow Net cash provided by operating activities was $244.6M, including $225.0M cash from GSK royalty sale.

YUPELRI China Approval Milestone Received $7.5M licensing revenue following YUPELRI regulatory approval by China NMPA in June 2025.

Risk Factors

Ampreloxetine Pipeline Uncertainty Phase 3 CYPRESS study last patient enrolled; top-line data expected in Q1 2026 for nOH indication.

Reliance on Viatris Partnership US commercial success relies on Viatris co-promotion efforts; failure impacts revenue and financial results.

Generic Competition Threat Litigation ongoing with Mankind Pharma regarding YUPELRI generics; settlements reached with most other filers.

Key Personnel Retention Risk Intense competition for skilled personnel in Northern California risks impairing development and commercialization efforts.

Outlook

Ampreloxetine Phase 3 Progress Expect top-line data availability for CYPRESS Phase 3 study in symptomatic nOH patients in Q1 2026.

Strategic Review Committee Active Board committee assessing strategic alternatives to unlock shareholder value; focus remains on disciplined capital allocation.

Liquidity Sufficient Twelve Months Expect current cash, cash equivalents, and marketable securities of $332.7M to fund operations for next twelve months.

Future Financing Needs Possible Future capital needs depend on YUPELRI support and ampreloxetine program expenditures; financing may require equity dilution.

Peer Comparison

Revenue (TTM)

ARVN

$262.60M

-0.3%

VALN

$198.55M

+13.5%

GERN

$183.88M

+138.8%

Gross Margin (Latest Quarter)

VIR

672.1%

-54902.1pp

ATXS

100.0%

+0.0pp

ABSI

100.0%

+197.2pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ERAS	$4.22B	-31.0	-34.5%	11.9%
TERN	$4.19B	-45.2	-30.0%	0.3%
DAWN	$2.20B	-20.5	-23.4%	0.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

2.2%

Moderate Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

50%

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 18, 2026

EPS:$1.09

Revenue:$50.70M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data